Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 83.6% in October

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 26,800 shares, a growth of 83.6% from the September 30th total of 14,600 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 32,100 shares, the short-interest ratio is currently 0.8 days.

Evogene Stock Up 2.5 %

Shares of NASDAQ EVGN traded up $0.06 during trading hours on Friday, hitting $2.46. The company had a trading volume of 36,120 shares, compared to its average volume of 19,951. The firm’s 50 day moving average is $2.93 and its 200-day moving average is $5.14. The stock has a market capitalization of $101.39 million, a P/E ratio of -5.28 and a beta of 1.40. Evogene has a 1-year low of $2.14 and a 1-year high of $10.40.

Evogene (NASDAQ:EVGN) last posted its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The business had revenue of $0.91 million for the quarter.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

EVGN has been the topic of a number of recent research reports. StockNews.com began coverage on Evogene in a research report on Friday. They issued a “sell” rating on the stock. Lake Street Capital reduced their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 23rd.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.